Renata PLC (DSE:RENATA)

Bangladesh · Delayed Price · Currency is BDT

449.10

+0.20 (0.04%)

At close: Sep 24, 2026

Market Cap	51.51B -6.6%
Revenue (ttm)	44.93B +8.6%
Net Income	2.73B -2.9%
EPS	23.81 -2.9%
Shares Out	114.70M
PE Ratio	18.86
Forward PE	16.38
Dividend	5.50 (1.23%)
Ex-Dividend Date	Nov 18, 2025

Volume	117,491
Open	451.50
Previous Close	448.90
Day's Range	447.50 - 452.00
52-Week Range	372.00 - 488.00
Beta	-0.00
Analysts	Strong Buy
Price Target	615.05 (+36.95%)
Est. Earnings	Oct 22, 2026

About Renata

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh and Portugal. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxi... [Read more]

Industry Pharmaceutical Preparations

Founded 1972

Employees 8,366

Stock Exchange Dhaka Stock Exchange

Ticker Symbol RENATA

Full Company Profile

Financial Performance

In fiscal year 2025, Renata's revenue was 42.89 billion, an increase of 13.74% compared to the previous year's 37.71 billion. Earnings were 2.22 billion, a decrease of -38.58%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for RENATA stock is "Strong Buy." The 12-month stock price target is ৳615.05, which is an increase of 36.95% from the latest price.

Price Target

৳615.05

(36.95% upside)

Analyst Consensus: Strong Buy

Stock Forecasts